OR WAIT null SECS
October 28, 2015.
According to a recent report from Citron Research originally highlighted in the New York Times (Oct. 19, 2015), Valeant is using phantom drug distribution companies to manipulate distribution numbers to auditors. Philidor Rx Services came on the media’s radar when Valeant CEO J. Michael Pearson said during a quarterly earnings call that Valeant had purchased an option to acquire Philidor in 2014.
BioPharm International's Randi Hernandez reports on Valeant's response here.